Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike

Rhea-AI Filing Summary

Sana Biotechnology director Robert L. Rosiello received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming he remains in continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rosiello Robert L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 90,000 shares Exercise price: $2.96 per share Total options after grant: 90,000 options +2 more

5 metrics

Option grant size 90,000 shares Stock Option (Right to Buy) underlying common stock

Exercise price $2.96 per share Conversion or exercise price of stock options

Total options after grant 90,000 options Total derivative securities following transaction

Expiration date June 3, 2036 Option expiration date

Vesting date June 4, 2027 Earlier of this date or 2027 annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vests and becomes exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "2.9600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

continuous service financial

"provided that the reporting person provides continuous service to Sana"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosiello Robert L.

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0.00	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Robert L. Rosiello	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Sana Biotechnology (SANA) director Robert Rosiello report on this Form 4?

Robert L. Rosiello reported receiving a grant of stock options for 90,000 Sana Biotechnology common shares. These options are a compensation award, not an open-market purchase or sale, and give him the right to buy shares in the future at a fixed price.

How many Sana Biotechnology (SANA) shares are covered by the new option grant?

The new option grant covers 90,000 shares of Sana Biotechnology common stock. This means Rosiello can potentially purchase up to 90,000 shares under this award if the options vest and he chooses to exercise them before expiration.

What is the exercise price and expiration date of Robert Rosiello’s SANA options?

The options have an exercise price of $2.96 per share and expire on June 3, 2036. This fixed price lets him buy shares at that level after vesting, regardless of the market price at that time.

When do Robert Rosiello’s Sana Biotechnology option awards vest?

The options vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting. Vesting is conditioned on Rosiello continuing to provide service to Sana Biotechnology through the applicable vesting date.

Is this Sana Biotechnology (SANA) Form 4 an insider purchase or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market purchase. The transaction code “A” and description show it is a stock option award, giving Rosiello rights to acquire shares in the future at $2.96 per share, subject to vesting.